Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.

ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events (AEs) are dependent on the route of administration has not been determined. We demonstrate that nearly identical exposure-response pharmacodynamic relationships are determined by plasma semaglutide levels achieved through oral versus injectable administration for changes in HbA_1c, body weight, biomarkers of cardiovascular risk, and AEs such as nausea and vomiting. At typical exposure levels for oral semaglutide, the estimated response is 1.58% (oral) versus -1.62% (subcutaneous) for HbA_1c and 3.77% (oral) versus 3.48% (subcutaneous) reduction in body weight relative to baseline after 6 months. Increased body weigh

SUBMITTER: Overgaard RV 

PROVIDER: S-EPMC8484505 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature